Core Insights - The company has undergone a comprehensive rebranding from N2OFF, Inc. to Nexentis Technologies Inc., reflecting its evolution into an innovative data-driven biotech firm focused on mitochondrial biology and precision oncology [1][2][4] - The rebranding is part of a strategic pivot that includes the integration of MitoCareX Bio Ltd., which is now a wholly-owned subsidiary, enhancing the company's drug discovery capabilities [3][6] Company Overview - Nexentis Technologies Inc. is focused on developing a pipeline of first-in-class small-molecule programs targeting mitochondrial SLC25 carriers, with applications in oncology and inflammatory metabolic diseases [3][5] - The company also maintains investments in solar energy assets through a Ready to Build (RTB) business model, which are considered non-core assets [1][3] Strategic Developments - The acquisition of MitoCareX on October 20, 2025, marked a significant shift from cleantech to biotechnology, establishing a foundation for the company's drug discovery strategy [6] - MitoCareX has validated its MITOLINE discovery platform, generating in vitro data that demonstrates anti-tumor activity and potential anti-inflammatory benefits, with markets for these indications projected to exceed $120 billion by 2030 [6] Research and Development Focus - The company is advancing a precision oncology and inflammation pipeline, targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, with plans for preclinical candidate nominations [6]

Core Insights - N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., focusing on the precision oncology market and leveraging MitoCareX's proprietary MITOLINE algorithm for drug discovery [1][2][3] Company Overview - MitoCareX Bio Ltd. is a biotechnology company utilizing MITOLINE, an algorithm for 3D modeling of mitochondrial transport proteins, to develop therapies for difficult-to-treat cancers [2][4] - The company targets mitochondrial SLC25 transport proteins, which are crucial in the metabolic reprogramming of aggressive cancers like lung and pancreatic cancer, with a projected global therapeutic market exceeding $50 billion by 2026 [3][4] Strategic Direction - MitoCareX aims to optimize hit-to-lead medicinal chemistry and pharmacokinetic profiling in 2026, with the goal of nominating a preclinical development candidate [5] - The company is exploring strategic collaborations and licensing agreements to expand MITOLINE's applications, creating non-dilutive revenue opportunities [6][7] Long-Term Vision - The long-term strategy includes preparing for IND-enabling studies to transition MitoCareX toward clinical readiness while establishing MITOLINE as a scalable discovery engine [7][8] - MitoCareX's approach combines mitochondrial biology, computational modeling, and precision oncology, positioning it uniquely in the biotech sector [8][9] Innovation and Value Creation - The MITOLINE algorithm enables high-throughput in silico screening of small molecules, accelerating the drug discovery process [4][10] - The company aims to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into sustained innovation and value creation [10][11]